AAPL325.07+8.22 (+2.59%) ▲|ABBV259.68+3.26 (+1.27%) ▲|ABT109.66-0.71 (-0.64%) ▼|ACN187.75-2.01 (-1.06%) ▼|ADBE288.74-4.06 (-1.39%) ▼|AMAT441.89-16.50 (-3.60%) ▼|AMD456.87-13.85 (-2.94%) ▼|AMGN432.62+2.74 (+0.64%) ▲|AMT175.81+0.11 (+0.06%) ▲|AMZN254.34-5.43 (-2.09%) ▼|AVGO369.35-0.99 (-0.27%) ▼|AXP324.37-5.80 (-1.76%) ▼|BA205.97-1.81 (-0.87%) ▼|BAC61.88-0.06 (-0.10%) ▼|BKNG197.78-1.31 (-0.66%) ▼|BLK1,128.07-27.54 (-2.38%) ▼|BMY66.88+0.07 (+0.10%) ▲|BNY159.62-1.67 (-1.03%) ▼|BRK-B504.49+0.46 (+0.09%) ▲|C132.22+0.60 (+0.46%) ▲|CAT775.29-22.18 (-2.78%) ▼|CL90.14+0.32 (+0.35%) ▲|CMCSA26.49-0.14 (-0.51%) ▼|COF211.57-2.95 (-1.37%) ▼|COP135.48+2.99 (+2.26%) ▲|COST945.20+1.31 (+0.14%) ▲|CRM257.75+0.21 (+0.08%) ▲|CSCO109.25-1.25 (-1.13%) ▼|CVS96.89+2.98 (+3.17%) ▲|CVX209.57+3.43 (+1.66%) ▲|DE668.09+13.18 (+2.01%) ▲|DHR207.42-6.14 (-2.88%) ▼|DIS106.84-0.71 (-0.66%) ▼|DUK119.94+0.03 (+0.02%) ▲|EMR147.92-4.52 (-2.97%) ▼|FDX320.70-6.70 (-2.05%) ▼|GD369.89-1.47 (-0.39%) ▼|GE330.54-5.17 (-1.54%) ▼|GEV891.14-7.39 (-0.82%) ▼|GILD148.62+2.28 (+1.56%) ▲|GM85.59-0.73 (-0.85%) ▼|GOOG332.21-3.20 (-0.95%) ▼|GOOGL335.40-3.95 (-1.16%) ▼|GS1,009.12-11.78 (-1.15%) ▼|HD319.73-8.10 (-2.47%) ▼|HON209.36-4.17 (-1.95%) ▼|IBM230.88-2.99 (-1.28%) ▼|INTC88.66-0.86 (-0.96%) ▼|INTU347.80-11.50 (-3.20%) ▼|ISRG367.98-8.89 (-2.36%) ▼|JNJ269.75+3.90 (+1.47%) ▲|JPM355.22-0.80 (-0.22%) ▼|KO88.12-0.56 (-0.63%) ▼|LIN482.96-6.62 (-1.35%) ▼|LLY1,163.21+6.48 (+0.56%) ▲|LMT545.22-12.56 (-2.25%) ▼|LOW201.02-3.68 (-1.80%) ▼|LRCX289.32-12.17 (-4.04%) ▼|MA585.27-4.04 (-0.69%) ▼|MCD261.51-0.17 (-0.07%) ▼|MDLZ61.85-0.22 (-0.35%) ▼|MDT92.73+2.08 (+2.29%) ▲|META580.80+8.46 (+1.48%) ▲|MMM169.99-1.84 (-1.07%) ▼|MO70.21+1.73 (+2.53%) ▲|MRK149.01+1.25 (+0.84%) ▲|MS211.93-1.39 (-0.65%) ▼|MSFT500.99-6.31 (-1.24%) ▼|MU941.30-17.43 (-1.82%) ▼|NEE82.45+0.11 (+0.13%) ▲|NFLX80.97-0.08 (-0.10%) ▼|NKE38.18-0.47 (-1.22%) ▼|NOW143.74-4.25 (-2.87%) ▼|NVDA218.33-2.17 (-0.98%) ▼|ORCL140.72-8.40 (-5.63%) ▼|PEP139.84-0.50 (-0.36%) ▼|PFE28.61+0.15 (+0.51%) ▲|PG146.19+1.07 (+0.74%) ▲|PLTR182.49-3.90 (-2.09%) ▼|PM189.36+2.06 (+1.10%) ▲|QCOM165.94-4.54 (-2.66%) ▼|RTX205.17-2.56 (-1.23%) ▼|SBUX105.51-0.74 (-0.70%) ▼|SCHW108.39-1.43 (-1.30%) ▼|SO87.86-0.14 (-0.16%) ▼|SPG212.14-0.18 (-0.08%) ▼|T26.11+0.22 (+0.83%) ▲|TMO602.10-15.00 (-2.43%) ▼|TMUS182.39+1.95 (+1.08%) ▲|TSLA357.15-10.80 (-2.94%) ▼|TXN251.54-9.37 (-3.59%) ▼|UBER75.45-0.20 (-0.26%) ▼|UNH395.02+5.61 (+1.44%) ▲|UNP289.90-10.77 (-3.58%) ▼|UPS102.06-2.17 (-2.08%) ▼|USB60.86-0.72 (-1.17%) ▼|V375.43-3.94 (-1.04%) ▼|VZ50.41+0.39 (+0.77%) ▲|WFC86.53+0.14 (+0.16%) ▲|WMT106.24+1.37 (+1.31%) ▲|XOM163.86+2.91 (+1.81%) ▲|AAPL325.07+8.22 (+2.59%) ▲|ABBV259.68+3.26 (+1.27%) ▲|ABT109.66-0.71 (-0.64%) ▼|ACN187.75-2.01 (-1.06%) ▼|ADBE288.74-4.06 (-1.39%) ▼|AMAT441.89-16.50 (-3.60%) ▼|AMD456.87-13.85 (-2.94%) ▼|AMGN432.62+2.74 (+0.64%) ▲|AMT175.81+0.11 (+0.06%) ▲|AMZN254.34-5.43 (-2.09%) ▼|AVGO369.35-0.99 (-0.27%) ▼|AXP324.37-5.80 (-1.76%) ▼|BA205.97-1.81 (-0.87%) ▼|BAC61.88-0.06 (-0.10%) ▼|BKNG197.78-1.31 (-0.66%) ▼|BLK1,128.07-27.54 (-2.38%) ▼|BMY66.88+0.07 (+0.10%) ▲|BNY159.62-1.67 (-1.03%) ▼|BRK-B504.49+0.46 (+0.09%) ▲|C132.22+0.60 (+0.46%) ▲|CAT775.29-22.18 (-2.78%) ▼|CL90.14+0.32 (+0.35%) ▲|CMCSA26.49-0.14 (-0.51%) ▼|COF211.57-2.95 (-1.37%) ▼|COP135.48+2.99 (+2.26%) ▲|COST945.20+1.31 (+0.14%) ▲|CRM257.75+0.21 (+0.08%) ▲|CSCO109.25-1.25 (-1.13%) ▼|CVS96.89+2.98 (+3.17%) ▲|CVX209.57+3.43 (+1.66%) ▲|DE668.09+13.18 (+2.01%) ▲|DHR207.42-6.14 (-2.88%) ▼|DIS106.84-0.71 (-0.66%) ▼|DUK119.94+0.03 (+0.02%) ▲|EMR147.92-4.52 (-2.97%) ▼|FDX320.70-6.70 (-2.05%) ▼|GD369.89-1.47 (-0.39%) ▼|GE330.54-5.17 (-1.54%) ▼|GEV891.14-7.39 (-0.82%) ▼|GILD148.62+2.28 (+1.56%) ▲|GM85.59-0.73 (-0.85%) ▼|GOOG332.21-3.20 (-0.95%) ▼|GOOGL335.40-3.95 (-1.16%) ▼|GS1,009.12-11.78 (-1.15%) ▼|HD319.73-8.10 (-2.47%) ▼|HON209.36-4.17 (-1.95%) ▼|IBM230.88-2.99 (-1.28%) ▼|INTC88.66-0.86 (-0.96%) ▼|INTU347.80-11.50 (-3.20%) ▼|ISRG367.98-8.89 (-2.36%) ▼|JNJ269.75+3.90 (+1.47%) ▲|JPM355.22-0.80 (-0.22%) ▼|KO88.12-0.56 (-0.63%) ▼|LIN482.96-6.62 (-1.35%) ▼|LLY1,163.21+6.48 (+0.56%) ▲|LMT545.22-12.56 (-2.25%) ▼|LOW201.02-3.68 (-1.80%) ▼|LRCX289.32-12.17 (-4.04%) ▼|MA585.27-4.04 (-0.69%) ▼|MCD261.51-0.17 (-0.07%) ▼|MDLZ61.85-0.22 (-0.35%) ▼|MDT92.73+2.08 (+2.29%) ▲|META580.80+8.46 (+1.48%) ▲|MMM169.99-1.84 (-1.07%) ▼|MO70.21+1.73 (+2.53%) ▲|MRK149.01+1.25 (+0.84%) ▲|MS211.93-1.39 (-0.65%) ▼|MSFT500.99-6.31 (-1.24%) ▼|MU941.30-17.43 (-1.82%) ▼|NEE82.45+0.11 (+0.13%) ▲|NFLX80.97-0.08 (-0.10%) ▼|NKE38.18-0.47 (-1.22%) ▼|NOW143.74-4.25 (-2.87%) ▼|NVDA218.33-2.17 (-0.98%) ▼|ORCL140.72-8.40 (-5.63%) ▼|PEP139.84-0.50 (-0.36%) ▼|PFE28.61+0.15 (+0.51%) ▲|PG146.19+1.07 (+0.74%) ▲|PLTR182.49-3.90 (-2.09%) ▼|PM189.36+2.06 (+1.10%) ▲|QCOM165.94-4.54 (-2.66%) ▼|RTX205.17-2.56 (-1.23%) ▼|SBUX105.51-0.74 (-0.70%) ▼|SCHW108.39-1.43 (-1.30%) ▼|SO87.86-0.14 (-0.16%) ▼|SPG212.14-0.18 (-0.08%) ▼|T26.11+0.22 (+0.83%) ▲|TMO602.10-15.00 (-2.43%) ▼|TMUS182.39+1.95 (+1.08%) ▲|TSLA357.15-10.80 (-2.94%) ▼|TXN251.54-9.37 (-3.59%) ▼|UBER75.45-0.20 (-0.26%) ▼|UNH395.02+5.61 (+1.44%) ▲|UNP289.90-10.77 (-3.58%) ▼|UPS102.06-2.17 (-2.08%) ▼|USB60.86-0.72 (-1.17%) ▼|V375.43-3.94 (-1.04%) ▼|VZ50.41+0.39 (+0.77%) ▲|WFC86.53+0.14 (+0.16%) ▲|WMT106.24+1.37 (+1.31%) ▲|XOM163.86+2.91 (+1.81%) ▲|
26.9 C
New York
Tuesday, September 1, 2026

Tag: medicine

newssourceFORcompanyinformationcontent1releasesmarket

Orbis International’s Flying Eye Hospital Arrives in Peru to Expand Access to Essential Eye Care

With support from Alcon, FedEx, and OMEGA, the Orbis Flying Eye Hospital returns to Peru to carry out a training project in the city of Arequipa.AREQUIPA,...

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation – IRON

NEW YORK, June 14, 2026 /PRNewswire/ -- ...

HorseWood & HorseBoost [Exclusive Report 2026] The Horse Gelatin Trick Male Enhancement Or Why Talking About Natural Vitality Supplement Horse Boost?

Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male performance, stamina, and confidence. 
Discover the truth behind HorseWood & HorseBoost in this 2026 exclusive report. Learn how the Horse Gelatin Trick works, what ingredients are included, and whether this natural vitality supplement can support male performance, stamina, and confidence.

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release

COPENHAGEN, Denmark; June 13, 2026

MGI Tech Showcases Expanding Genomics Ecosystem at ESHG 2026 with New IVD Partnering Program and OEM Collaborations

GOTHENBURG, Sweden, June 13, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation...

Readout -Prime Minister Carney meets with Taoiseach of Ireland Micheál Martin

DUBLIN, Ireland, June 13, 2026 /CNW/ - Today, the Prime Minister, Mark Carney, met with the Taoiseach of Ireland, Micheál Martin, during his bilateral...

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that...

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.1  

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary

SHANGHAI, June 12, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, recently marked its 40th anniversary with the release...

Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary

SHANGHAI, June 13, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, recently marked its 40th anniversary with the release...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicine

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers